Cell Medica, a specialist in cellular immunotherapy for the treatment of cancer, announced the appointment of Kevin S. Boyle Senior, as Chief Financial Officer, based in Houston, TX.
With more than 20 years of financial and capital markets experience, Boyle joins the Senior Executive team as the company prepares for ground-breaking clinical trials to investigate cancer treatments utilising Cell Medica’s innovative chimeric antibody receptor (CAR) and engineered T cell receptor (TCR) cell therapies.
Boyle has held senior finance roles at both NASDAQ-listed and private equity backed companies. He is an accomplished capital markets professional with strong banking relationships cultivated by raising more than $2.0 billion in equity and debt capital.
At Cell Medica, Boyle will play a lead role in both corporate strategy and financial planning as the company progresses with an exciting pipeline of CAR and TCR products in both the US and Europe. Boyle received a law degree from the University of Pennsylvania and a Bachelor of Science degree in Industrial Management and Economics from Carnegie Mellon University.
Gregg Sando, CEO Cell Medica, said: “We look forward to Kevin joining Cell Medica as we prepare for significant growth in our CAR and TCR development activities. His US capital markets experience and proven deal-making acumen will complement the capabilities of our current senior management team and help us realise the immense potential of our cell-based immunotherapies for the treatment of cancer patients.”